{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:20:15Z","timestamp":1792592415904,"version":"4.5.0"},"reference-count":70,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>CONTEXT:<\/jats:title>\n                  <jats:p>Functional abdominal pain disorders (FAPDs) are common in childhood, impacting quality of life and school attendance. There are several compounds available for the treatment of pediatric FAPDs, but their efficacy and safety are unclear because of a lack of head-to-head randomized controlled trials (RCTs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVE:<\/jats:title>\n                  <jats:p>To systematically review the efficacy and safety of the pharmacologic treatments available for pediatric FAPDs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA SOURCES:<\/jats:title>\n                  <jats:p>Electronic databases were searched from inception to February 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY SELECTION:<\/jats:title>\n                  <jats:p>RCTs or systematic reviews were included if the researchers investigated a study population of children (4\u201318 years) in whom FAPDs were treated with pharmacologic interventions and compared with placebo, no treatment, or any other agent.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA EXTRACTION:<\/jats:title>\n                  <jats:p>Two reviewers independently performed data extraction and assessed their quality. Any interresearcher disagreements in the assessments were resolved by a third investigator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Seventeen articles representing 1197 children with an FAPD were included. Trials investigating antispasmodics, antidepressants, antibiotics, antihistaminic, antiemetic, histamine-2-receptor antagonist, 5-HT4-receptor agonist, melatonin, and buspirone were included. No studies were found on treatment with laxatives, antidiarrheals, analgesics, antimigraines, and serotonergics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>LIMITATIONS:<\/jats:title>\n                  <jats:p>The overall quality of evidence on the basis of the Grading of Recommendations, Assessment, Development and Evaluations system was very low to low.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>On the basis of current evidence, it is not possible to recommend any specific pharmacologic agent for the treatment of pediatric FAPDs. However, agents such as antispasmodics or antidepressants can be discussed in daily practice because of their favorable treatment outcomes and the lack of important side effects. High-quality RCTs are necessary to provide adequate pharmacologic treatment. For future intervention trials, we recommend using homogenous outcome measures and instruments, a large sample size, and long-term follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2020-042101","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T08:25:17Z","timestamp":1622103917000},"source":"Crossref","is-referenced-by-count":51,"title":["Pharmacologic Treatment in Functional Abdominal Pain Disorders in Children: A Systematic Review"],"prefix":"10.1542","volume":"147","author":[{"given":"Robyn","family":"Rexwinkel","sequence":"first","affiliation":[{"name":"Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children\u2019s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands;"},{"name":"Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, Academic Medical Center and Emma Children\u2019s Hospital, Amsterdam, The Netherlands;"},{"name":"Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and"},{"name":"Contributed equally as co-first authors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara M. A.","family":"de Bruijn","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children\u2019s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands;"},{"name":"Amsterdam Reproduction and Development Research Institute, Amsterdam University Medical Center, Academic Medical Center and Emma Children\u2019s Hospital, Amsterdam, The Netherlands;"},{"name":"Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands; and"},{"name":"Contributed equally as co-first authors"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Gordon","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Central Lancashire, Preston, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Benninga","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children\u2019s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit M.","family":"Tabbers","sequence":"additional","affiliation":[{"name":"Pediatric Gastroenterology, Hepatology, and Nutrition, Emma Children\u2019s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,6,1]]},"reference":[{"issue":"5","key":"2022050217154658700_B1","doi-asserted-by":"crossref","first-page":"e0126982","DOI":"10.1371\/journal.pone.0126982","article-title":"Epidemiology of pediatric functional abdominal pain disorders: a meta-analysis","volume":"10","author":"Korterink","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"2022050217154658700_B2","doi-asserted-by":"crossref","first-page":"P1456","DOI":"10.1053\/j.gastro.2016.02.015","article-title":"Childhood functional gastrointestinal disorders: child\/adolescent","volume":"150","author":"Hyams","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"2022050217154658700_B3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2007.12.019","article-title":"Chronic abdominal pain and depressive symptoms: analysis of the national longitudinal study of adolescent health","volume":"6","author":"Youssef","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"2022050217154658700_B4","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jpeds.2015.07.058","article-title":"Annual costs of care for pediatric irritable bowel syndrome, functional abdominal pain, and functional abdominal pain syndrome","volume":"167","author":"Hoekman","year":"2015","journal-title":"J Pediatr"},{"key":"2022050217154658700_B5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jpeds.2016.04.008","article-title":"Prevalence of functional gastrointestinal disorders in children and adolescents","volume":"177","author":"Lewis","year":"2016","journal-title":"J Pediatr"},{"issue":"5","key":"2022050217154658700_B6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/MPG.0000000000000850","article-title":"School attendance in children with functional abdominal pain and inflammatory bowel diseases","volume":"61","author":"Assa","year":"2015","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2022050217154658700_B7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MPG.0b013e3181de0639","article-title":"A million-dollar work-up for abdominal pain: is it worth it?","volume":"51","author":"Dhroove","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2022050217154658700_B8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.pain.2010.06.018","article-title":"Functional abdominal pain in childhood and adolescence increases risk for chronic pain in adulthood","volume":"150","author":"Walker","year":"2010","journal-title":"Pain"},{"issue":"3","key":"2022050217154658700_B9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/MPG.0b013e31815bc1c1","article-title":"Prognosis of chronic or recurrent abdominal pain in children","volume":"47","author":"Gieteling","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"2022050217154658700_B10","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2014.03.034","article-title":"Predicting persistence of functional abdominal pain from childhood into young adulthood","volume":"12","author":"Horst","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2022050217154658700_B11","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/j.1572-0241.2005.41753.x","article-title":"The natural history of childhood abdominal pain and its association with adult irritable bowel syndrome: birth-cohort study","volume":"100","author":"Howell","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"2022050217154658700_B12","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2017.11.279","article-title":"Neuromodulators for functional gastrointestinal disorders (disorders of gut-brain interaction): a Rome Foundation Working Team Report","volume":"154","author":"Drossman","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"2022050217154658700_B13","doi-asserted-by":"crossref","first-page":"P1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"2022050217154658700_B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nrgastro.2015.21","article-title":"Childhood functional abdominal pain: mechanisms and management","volume":"12","author":"Korterink","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2022050217154658700_B15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jpeds.2014.09.067","article-title":"Pharmacologic treatment in pediatric functional abdominal pain disorders: a systematic review","volume":"166","author":"Korterink","year":"2015","journal-title":"J Pediatr"},{"key":"2022050217154658700_B16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jpeds.2020.02.032","article-title":"A core outcome set for clinical trials in pediatric functional abdominal pain disorders","volume":"221","author":"Zeevenhooven","year":"2020","journal-title":"J Pediatr"},{"key":"2022050217154658700_B17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7650","key":"2022050217154658700_B18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2022050217154658700_B19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/9781119536604.ch15","article-title":"Interpreting Results and Drawing Conclusions","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Sch\u00fcnemann","year":"2019","edition":"2nd ed"},{"issue":"1","key":"2022050217154658700_B20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MPG.0000000000001922","article-title":"Recurrent abdominal pain in children: summary evidence from 3 systematic reviews of treatment effectiveness","volume":"67","author":"Abbott","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"2022050217154658700_B21","first-page":"CD003960","article-title":"Tegaserod for the treatment of irritable bowel syndrome and chronic constipation","author":"Evans","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2022050217154658700_B22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1080\/17512433.2018.1540298","article-title":"Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review","volume":"11","author":"Browne","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"2022050217154658700_B23","first-page":"CD003017","article-title":"Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood","author":"Huertas-Ceballos","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2022050217154658700_B24","first-page":"CD003017","article-title":"Pharmacological interventions for recurrent abdominal pain (RAP) in childhood (review)","author":"Huertas-Ceballos","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2022050217154658700_B25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2710.2002.00426.x","article-title":"A systematic review of tegaserod for the treatment of irritable bowel syndrome","volume":"27","author":"Jones","year":"2002","journal-title":"J Clin Pharm Ther"},{"issue":"7","key":"2022050217154658700_B26","first-page":"CD008013","article-title":"Antidepressants for the treatment of abdominal pain-related functional gastrointestinal disorders in children and adolescents","author":"Kaminski","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2022050217154658700_B27","first-page":"CD010973","article-title":"Pharmacological interventions for recurrent abdominal pain in childhood","author":"Martin","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"2022050217154658700_B28","first-page":"CD003460","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2022050217154658700_B29","doi-asserted-by":"crossref","DOI":"10.1542\/peds.111.1.e1","article-title":"Systematic review of treatments for recurrent abdominal pain","volume":"111","author":"Weydert","year":"2003","journal-title":"Pediatrics"},{"issue":"10","key":"2022050217154658700_B30","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s13312-015-0730-y","article-title":"Efficacy and safety of drotaverine hydrochloride in children with recurrent abdominal pain: a randomized placebo controlled trial","volume":"52","author":"Narang","year":"2015","journal-title":"Indian Pediatr"},{"issue":"1","key":"2022050217154658700_B31","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4292\/wjgpt.v7.i1.156","article-title":"Therapeutic effect of melatonin on pediatric functional dyspepsia: a pilot study","volume":"7","author":"Zybach","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"1","key":"2022050217154658700_B32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5056\/jnm.2013.19.1.90","article-title":"The incidence of irritable bowel syndrome in children using the Rome iii criteria and the effect of trimebutine treatment","volume":"19","author":"Karabulut","year":"2013","journal-title":"J Neurogastroenterol Motil"},{"issue":"1","key":"2022050217154658700_B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1067\/mpd.2001.109606","article-title":"Enteric-coated, pH-dependent peppermint oil capsules for the treatment of irritable bowel syndrome in children","volume":"138","author":"Kline","year":"2001","journal-title":"J Pediatr"},{"issue":"11","key":"2022050217154658700_B34","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1111\/nmo.12444","article-title":"Citalopram for pediatric functional abdominal pain: a randomized, placebo-controlled trial","volume":"26","author":"Roohafza","year":"2014","journal-title":"Neurogastroenterol Motil"},{"key":"2022050217154658700_B35","doi-asserted-by":"crossref","first-page":"191026","DOI":"10.1155\/2014\/191026","article-title":"Mebeverine for pediatric functional abdominal pain: a randomized, placebo-controlled trial","volume":"2014","author":"Pourmoghaddas","year":"2014","journal-title":"BioMed Res Int"},{"issue":"6","key":"2022050217154658700_B36","first-page":"1367","article-title":"Cyproheptadine for the treatment of functional abdominal pain in childhood: a double-blinded randomized placebo-controlled trial","volume":"60","author":"Sadeghian","year":"2008","journal-title":"Minerva Pediatr"},{"issue":"4","key":"2022050217154658700_B37","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1053\/j.gastro.2009.06.060","article-title":"Multicenter, randomized, placebo-controlled trial of amitriptyline in children with functional gastrointestinal disorders","volume":"137","author":"Saps","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"2022050217154658700_B38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1023\/A:1010793408132","article-title":"Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment","volume":"46","author":"See","year":"2001","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2022050217154658700_B39","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/adc.73.2.183-a","article-title":"Double blind placebo controlled trial of pizotifen syrup in the treatment of abdominal migraine","volume":"73","author":"Symon","year":"1995","journal-title":"Arch Dis Child"},{"issue":"4","key":"2022050217154658700_B40","doi-asserted-by":"crossref","first-page":"e23844","DOI":"10.5812\/ircmj.17(4)2015.23844","article-title":"Comparison of the effects of pH-dependent peppermint oil and synbiotic lactol (Bacillus coagulans + Fructooligosaccharides) on childhood functional abdominal pain: a randomized placebo-controlled study","volume":"17","author":"Asgarshirazi","year":"2015","journal-title":"Iran Red Crescent Med J"},{"issue":"5","key":"2022050217154658700_B41","doi-asserted-by":"crossref","first-page":"756","DOI":"10.14309\/ajg.0000000000000589","article-title":"Comparison of the efficacy of buspirone and placebo in childhood functional abdominal pain: a randomized clinical trial","volume":"115","author":"Badihian","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2022050217154658700_B42","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jpeds.2007.10.012","article-title":"Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents","volume":"152","author":"Bahar","year":"2008","journal-title":"J Pediatr"},{"issue":"4","key":"2022050217154658700_B43","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/MPG.0b013e3181effa3b","article-title":"Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain","volume":"52","author":"Collins","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2022050217154658700_B44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/MPG.0b013e31823a29a7","article-title":"No advantage for antibiotic treatment over placebo in Blastocystis hominis-positive children with recurrent abdominal pain","volume":"54","author":"Heyland","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2022050217154658700_B45","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/MPG.0000000000001819","article-title":"Randomized controlled clinical trial on value of domperidone in functional abdominal pain in children","volume":"66","author":"Karunanayake","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"2022050217154658700_B46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2036.2006.02705.x","article-title":"Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome","volume":"23","author":"Khoshoo","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2022050217154658700_B47","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2468-1253(19)30324-3","article-title":"Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis","volume":"5","author":"Black","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"2022050217154658700_B48","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"2022050217154658700_B49","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S2468-1253(19)30256-0","article-title":"New advances in the treatment of paediatric functional abdominal pain disorders","volume":"5","author":"Santucci","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"2022050217154658700_B50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea","volume":"374","author":"Lembo","year":"2016","journal-title":"N Engl J Med"},{"key":"2022050217154658700_B51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/CEG.S123621","article-title":"Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea","volume":"10","author":"Fragkos","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"2022050217154658700_B52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2018.1527303","article-title":"Long-term treatment with plecanatide was safe and tolerable in patients with irritable bowel syndrome with constipation","volume":"35","author":"Barish","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2022050217154658700_B53","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","article-title":"Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis","volume":"155","author":"Black","year":"2018","journal-title":"Gastroenterology"},{"key":"2022050217154658700_B54","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/PHMT.S159925","article-title":"Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome","volume":"9","author":"Arrouk","year":"2018","journal-title":"Pediatric Health Med Ther"},{"issue":"5","key":"2022050217154658700_B55","doi-asserted-by":"crossref","first-page":"S652","DOI":"10.1016\/S0016-5085(17)32299-0","article-title":"Safety, tolerability, and efficacy of serum-derived bovine immunoglobulin in children with diarrhea-predominant irritable bowel syndrome","volume":"152","author":"Rana","year":"2017","journal-title":"Gastroenterology"},{"issue":"4","key":"2022050217154658700_B56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2009.08.023","article-title":"The power of placebo in pediatric functional gastrointestinal disease","volume":"137","author":"Benninga","year":"2009","journal-title":"Gastroenterology"},{"key":"2022050217154658700_B57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2016.12.022","article-title":"The placebo response in pediatric abdominal pain-related functional gastrointestinal disorders: a systematic review and meta-analysis","volume":"182","author":"Hoekman","year":"2017","journal-title":"J Pediatr"},{"issue":"3","key":"2022050217154658700_B58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S1542-3565(04)00626-3","article-title":"Defining the predictors of the placebo response in irritable bowel syndrome","volume":"3","author":"Pitz","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2022050217154658700_B59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2022050217154658700_B60","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2982.2005.00650.x","article-title":"The placebo effect in irritable bowel syndrome trials: a meta-analysis","volume":"17","author":"Patel","year":"2005","journal-title":"Neurogastroenterol Motil"},{"issue":"8","key":"2022050217154658700_B61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1365-2982.2007.00937.x","article-title":"A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome","volume":"19","author":"Dorn","year":"2007","journal-title":"Neurogastroenterol Motil"},{"issue":"8","key":"2022050217154658700_B62","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrgastro.2015.117","article-title":"Placebo effects and their determinants in gastrointestinal disorders","volume":"12","author":"Elsenbruch","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2022050217154658700_B63","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ctim.2012.12.003","article-title":"The placebo effect revisited: lessons learned to date","volume":"21","author":"Kirsch","year":"2013","journal-title":"Complement Ther Med"},{"issue":"7","key":"2022050217154658700_B64","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/PSY.0b013e3181acee12","article-title":"Patient and practitioner influences on the placebo effect in irritable bowel syndrome","volume":"71","author":"Kelley","year":"2009","journal-title":"Psychosom Med"},{"issue":"7651","key":"2022050217154658700_B65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"BMJ"},{"issue":"2","key":"2022050217154658700_B66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14740338.2019.1574295","article-title":"Side effects associated with pharmacotherapy for pediatric irritable bowel syndrome and functional abdominal pain - not otherwise specified: a systematic review","volume":"18","author":"Rexwinkel","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2022050217154658700_B67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/2050640620967899","article-title":"Sample-size estimation is not reported in 24% of randomised controlled trials of inflammatory bowel disease: a systematic review","volume":"9","author":"Iheozor-Ejiofor","year":"2020","journal-title":"United European Gastroenterol J"},{"issue":"11","key":"2022050217154658700_B68","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/nmo.12896","article-title":"Recommendations for pharmacological clinical trials in children with irritable bowel syndrome: the Rome foundation pediatric subcommittee on clinical trials","volume":"28","author":"Saps","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"2022050217154658700_B69","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"issue":"3","key":"2022050217154658700_B70","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1542\/peds.2014-2123","article-title":"Nonpharmacologic treatment of functional abdominal pain disorders: a systematic review","volume":"135","author":"Rutten","year":"2015","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-042101\/1282824\/peds_2020042101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-042101\/1282824\/peds_2020042101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T17:16:45Z","timestamp":1651511805000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/147\/6\/e2020042101\/180271\/Pharmacologic-Treatment-in-Functional-Abdominal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":70,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,1]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-042101","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,1]]},"article-number":"e2020042101"}}